Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 11/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.57 |
| ▸ | HTR2A | P28223 | 4/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.57 |
| ▸ | AR | P10275 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.50 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.50 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4186077 | 0.84 | AR (0.67) | SLC22A12CYP2C19KDM4EMEN1ALDH1A1 | |
| SCHEMBL9121316 | 0.83 | AR (0.61) | SLC22A12CYP2C19KDM4EMEN1ALDH1A1 | |
| SCHEMBL28288101 | 0.82 | HTR2A (0.55) | SLC22A12CYP2C19KDM4EMEN1ALDH1A1 | |
| SCHEMBL14081445 | 0.82 | AR (0.57) | SLC22A12KCNH2HTR2ASLC6A4AR | |
| SCHEMBL4181443 | 0.81 | AR (0.72) | SLC22A12CYP2C19KDM4EMEN1ALDH1A1 | |
| SCHEMBL4182051 | 0.80 | AR (0.59) | SLC22A12CYP2C19KCNH2HTR2ASLC6A4 | |
| SCHEMBL16059840 | 0.79 | SLC22A12 (0.48) | SLC22A12CYP2C19KDM4EMEN1ALDH1A1 | |
| SCHEMBL11752736 | 0.78 | AR (0.57) | SLC22A12KDM4EMEN1ALDH1A1HPGD | |
| SCHEMBL5949965 | 0.78 | AR (0.56) | SLC22A12ARPLA2G7 | |
| SCHEMBL4103326 | 0.78 | HTR2A (0.53) | SLC22A12KDM4EMEN1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7084165-B2 | Monoamine reuptake inhibitors for treatment of CNS disorders | PFIZER INC (US) | 2006-08-01 | — | — | US | disclosed |
| US-20040048856-A1 | Monoamine reuptake inhibitors for treatment of CNS disorders | PFIZER INC | 2004-03-11 | — | — | US | disclosed |
| US-6677378-B2 | AS SEROTONIN, NOREPINEPHRINE AND DOPAMINE REUPTAKE INHIBITORS, FOR THERAPY OF CENTRAL NERVOUS SYSTEM AND OTHER DISORDERS | PFIZER INC. | 2004-01-13 | — | — | US | disclosed |
| US-20020143003-A1 | Monoamine reuptake inhibitors for treatment of CNS disorders | PFIZER INC. | 2002-10-03 | — | — | US | disclosed |
| EP-1154984-A1 | INHIBITORS FOR UPTAKE OF SEROTONINE, DOPAMINE OR NOREPINEPHRINE | Pfizer Products Inc. (US) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000050380-A1 | MONOAMINE REUPTAKE INHIBITORS FOR TREATMENT OF CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143003-A1 | Monoamine reuptake inhibitors for treatment of CNS disorders | SLC6A2, SLC6A4, SLC6A3 | SLC22A12 406/4885CYP2C19 195/4885KDM4E 786/4885 |
| US-20040048856-A1 | Monoamine reuptake inhibitors for treatment of CNS disorders | SLC6A2, SLC6A3, SLC18A2 | SLC22A12 238/4885CYP2C19 303/4885KDM4E 2256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.